Pfizer Inc. / Icagen, Inc.

Chronic Pain and Sensory Disorders

Disease Overview

Chronic pain affects roughly 1 in 5 US adults and is a leading driver of disability, opioid prescribing, and healthcare spend. Existing analgesics (opioids, NSAIDs, gabapentinoids) carry significant tolerability and abuse-liability problems, leaving major unmet need for non-opioid mechanisms. Selective ion-channel modulation has emerged as a leading strategy because rare human Nav1.7 mutations validate the target genetically.

Competitive Landscape

The non-opioid pain landscape in 2011 was dominated by older mechanisms — Lyrica (pregabalin), Cymbalta (duloxetine), Lidoderm (lidocaine patch) — none of them ion-channel-selective. Genuine selective Nav inhibitors were almost entirely preclinical. Vertex (VX-150, later VX-548/suzetrigine), Convergence Pharmaceuticals (raxatrigine), and Xenon Pharmaceuticals were the main competitors pursuing the same Nav1.7/Nav1.8 thesis as Icagen. Pfizer's earlier 2007 collaboration with Icagen had already focused on three sodium channels for pain; the 2011 buyout consolidated those programs inside Pfizer's Neusentis pain unit and removed a public-market platform from competitive reach. The deal mattered less for revenue (sub-$60M) than as a platform tuck-in: it gave Pfizer the cell lines, screening assets and ion-channel scientists that fed Neusentis's analgesic discovery pipeline. Pfizer ultimately deprioritized the platform and divested it to XRpro Sciences in 2015 for $0.5M upfront plus up to $10.5M in milestones, signaling that no late-stage candidate had emerged. The strategic thesis — that selective Nav inhibition would replace opioids — was vindicated more than a decade later when Vertex's suzetrigine (Journavx) won FDA approval in 2025.